Close

LANXESS: Price adjustment for PA 6.6 compounds

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Novo Nordisk and AWS Enter Strategic AI Partnership to Accelerate Drug Discovery

Novo Nordisk has announced a strategic partnership with Amazon...

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals

The Trump administration is preparing to announce a new...

Huawei Expands AI Drug Discovery Ambitions Amid Domestic Chip Push and Policy Support

Huawei intends to deepen its artificial intelligence partnerships with...
- Advertisement -

LANXESS is raising its prices for Durethan A (polyamide 6.6) compounds in Europe, Middle East and Africa by EUR 0.60/kg with immediate effect.

The overall tight market situation with extremely limited availability of raw materials in the PA 6.6 value chain has led to further severe price increases for PA 6.6 base resin.

As there are no signs of a relief, a price adjustment is unavoidable.

The High Performance Materials business unit offers support in exploring opportunities to replace PA 6.6 applications by PA 6 or PBT grades.

About LANXESS
LANXESS is a leading specialty chemicals company with sales of EUR 9.7 billion in 2017 and about 19,200 employees in 25 countries. The company is currently represented at 74 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. Through ARLANXEO, the joint venture with Saudi Aramco, LANXESS is also a leading supplier of synthetic rubber. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Novo Nordisk and AWS Enter Strategic AI Partnership to Accelerate Drug Discovery

Novo Nordisk has announced a strategic partnership with Amazon...

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals

The Trump administration is preparing to announce a new...

Huawei Expands AI Drug Discovery Ambitions Amid Domestic Chip Push and Policy Support

Huawei intends to deepen its artificial intelligence partnerships with...

McKesson to Acquire Precision Medicine Group for $2.25 Billion

US-based healthcare services provider McKesson has agreed to acquire...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »